Azerbaijan Pharmaceutical Country Profile
Total Page:16
File Type:pdf, Size:1020Kb
Azerbaijan PHARMACEUTICAL COUNTRY PROFILE Azerbaijan Pharmaceutical Country Profile Published by the Ministry of Health in collaboration with the World Health Organization 12/05/2011 Any part of this document may be freely reviewed, quoted, reproduced, or translated in full or in part, provided that the source is acknowledged. It may not be sold, or used in conjunction with commercial purposes or for profit. This document was produced with the support of the World Health Organization (WHO) Azerbaijan Country Office, and all reasonable precautions have been taken to verify the information contained herein. The published material does not imply the expression of any opinion whatsoever on the part of the World Health Organization, and is being distributed without any warranty of any kind – either expressed or implied. The responsibility for interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. ii Foreword The 2011 Pharmaceutical Country Profile for Azerbaijan has been produced by the Ministry of Health, in collaboration with the World Health Organization. This document contains information on existing socio-economic and health- related conditions, resources; as well as on regulatory structures, processes and outcomes relating to the pharmaceutical sector in Azerbaijan. The compiled data comes from international sources (e.g. the World Health Statistics1,2), surveys conducted in the previous years and country level information collected in 2011. The sources of data for each piece of information are presented in the tables that can be found at the end of this document. On the behalf of the Ministry of Azerbaijan, I wish to express my appreciation to WHO Country Office in Azerbaijan for its contribution to the process of data collection and the development of this profile. It is my hope that partners, researchers, policy-makers and all those who are interested in the Azerbaijan pharmaceutical sector will find this profile a useful tool to aid their activities. Name: Rashida Abdullayeva Function in the Ministry of Health: Head of Drug Procurement Planning and Rational Drug Use; department of Innovation and Supply Centre Date: 12/05/2011 Signature iii Table of content Foreword.............................................................................................................. iii Table of content ................................................................................................... iv Introduction ...........................................................................................................1 Section 1 - Health and Demographic Data........................................................2 Section 2 - Health Services ................................................................................5 Section 3 - Policy Issues ....................................................................................9 Section 4 – Medicines Trade and Production.................................................11 Section 5 – Medicines Regulation ...................................................................13 Section 6 - Medicines Financing......................................................................20 Section 7 - Pharmaceutical procurement and distribution in the public sector .................................................................................................................23 Section 8 - Selection and rational use of medicines......................................24 Section 9 - Household data/access .................................................................28 iv Introduction This Pharmaceutical Country Profile provides data on existing socio-economic and health-related conditions, resources, regulatory structures, processes and outcomes relating to the pharmaceutical sector of Azerbaijan. The aim of this document is to compile all relevant, existing information on the pharmaceutical sector and make it available to the public in a user-friendly format. In 2010, the country profiles project was piloted in 13 countries (http://www.who.int/medicines/areas/coordination/coordination_assessment/en/in dex.html). During 2011, the World Health Organization has supported all WHO Member States to develop similar comprehensive pharmaceutical country profiles. The information is categorized in 9 sections, namely: (1) Health and Demographic data, (2) Health Services, (3) Policy Issues, (4) Medicines Trade and Production (5) Medicines Regulation, (6) Medicines Financing, (7) Pharmaceutical procurement and distribution, (8) Selection and rational use, and (9) Household data/access. The indicators have been divided into two categories, namely "core" (most important) and "supplementary" (useful if available). This narrative profile is based on data derived from both the core and supplementary indicators. The tables in the annexes also present all data collected for each of the indicators in the original survey form. For each piece of information, the year and source of the data are indicated; these have been used to build the references in the profile and are also indicated in the tables. If key national documents are available on-line, links have been provided to the source documents so that users can easily access these documents. The selection of indicators for the profiles has involved all technical units working in the Essential Medicines Department of the World Health Organization (WHO), as well as experts from WHO Regional and Country Offices, Harvard Medical 1 School, Oswaldo Cruz Foundation (known as Fiocruz), University of Utrecht, the Austrian Federal Institute for Health Care and representatives from 13 pilot countries. Data collection in all 193 member states has been conducted using a user- friendly electronic questionnaire that included a comprehensive instruction manual and glossary. Countries were requested not to conduct any additional surveys, but only to enter the results from previous surveys and to provide centrally available information. To facilitate the work of national counterparts, the questionnaires were pre-filled at WHO HQ using all publicly-available data and before being sent out to each country by the WHO Regional Office. A coordinator was nominated for each of the member states. The coordinator for Azerbaijan was Rashida Abdullayeva. The completed questionnaires were then used to generate individual country profiles. In order to do this in a structured and efficient manner, a text template was developed. Experts from member states took part in the development of the profile and, once the final document was ready, an officer from the Ministry of Health certified the quality of the information and gave formal permission to publish the profile on the WHO web site. This profile will be regularly updated by the Ministry of Health of Azerbaijan. Comments, suggestions or corrections may be sent to: Rashida Abdullayeva Haji Hasan road 3 Baku AZ0100 994 12 3462452, 994 12 3461133 [email protected] 2 Section 1 - Health and Demographic Data This section gives an overview of the demographics and health status of Azerbaijan. 1.1 Demographics and Socioeconomic Indicators The total population of Azerbaijan in 2010 was 8,997,400 with an annual population growth rate of 1.0%3. The annual GDP growth rate is 5.0%4. The GDP per capita was US$5,845.20 (at the current exchange ratei). 1.2 Mortality and Causes of Death The life expectancy at birth is 70.9 and 76.1 years for men and women respectively. The infant mortality rate (i.e. children under 1 year) is 11.1/1,000 live births. For children under the age of 5, the mortality rate is 14.4/1,000 live births. The maternal mortality rate is 24.3/100,000 live births5. The top 10 diseases causing mortality in Azerbaijan are [Annual Statistical Report available on www.azstat.org]: Disease 1 Diseases of the circulatory - cardiovascular system 2 Neoplasm’s 3 Diseases of the digestive system 4 Accidents, poisonings, injuries 5 Diseases of respiratory system 6 Diseases of the genitourinary system 7 Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified 8 Endocrine system diseases, digestive disturbance, disturbance of metabolism and immunity 9 Certain infections and parazitic deseases 10 Congenital anomaly i The exchange rate for calculation for NCU is 1 AZN = 1.265 USD (06/05/11-d/m/y) 3 The top 10 diseases causing morbidity in Azerbaijan are [Annual Statistical Report available on http://www.azstat.org]: Disease 1 Diseases of respiratory system 2 Certain infections and parazitic deseases 3 Diseases of the digestive system 4 Diseases of the circulatory - cardiovascular system 5 Diseases of the genitourinary system 6 Skin deseases 7 Diseases of nervous system 8 Endocrine system diseases, digestive disturbance, disturbance of metabolism and immunity 9 Blood disorders and immune system disturbances 10 Pregnancy, labor, puerperal period 4 Section 2 - Health Services This section provides information regarding health expenditures and human resources for health in Azerbaijan. The contribution of the public and private sector to overall health expenditure is shown and the specific information on pharmaceutical expenditure is also presented. Data on human resources for health and for the pharmaceutical sector is provided as well. 2.1 Health Expenditures In Azerbaijan, the total annual expenditure on health (THE) in 2008 was 1,377 million AZN (US$1,742 million)6. The total annual health expenditure was 3.3% of the